CD68 and neoplasm: Further secondary endpoint analyses showed that focusing on myeloid subsets revealed that sitravatinib monotherapy or in combination with nivolumab did not significantly change the number of macrophages, the percentage PD-L1 expression in CD68+ (Fig. 6), or the myeloid cell M1:M2 macrophage ratio (Supplementary Fig. S5) in tumour tissues.